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An increasing number of patients with cartilage
defects of the knee are being treated with autologous
chondrocyte implantation (ACI). To date, no clear
guidelines exist for the use and indications of this
technique. The BVOT and SOBCOT have estab-
lished a working group to review the clinical results
and the cost-effectiveness of the various treatment
modalities and particularly of ACI. This group has
formulated recommendations and presents a treat-
ment algorithm based on an in-depth review of
recent European and American literature, on peer-
reviewed opinions of leading investigators in the field
and on a comparative analysis of the clinical results
and health-economic aspects of current cartilage
repair techniques.
Keywords : knee ; cartilage defects ; autologous carti-
lage implantation.
Cartilage defects and their implications
A large number of patients consult an
orthopaedic surgeon because of a joint problem
related to damage to the articular cartilage. A chon-
dral lesion was found in 63% of 31,516 arthro-
scopies retrospectively analysed by Curl et al (29)
in 1997 ; almost 20% of the lesions were Grade 4
(Outerbridge Scale) and were mainly located on the
medial femoral condyle. Four percent were single
lesions in patients under 40 years of age (29).
Similar data were reported in two more recent pub-
lications by Hjelle et al (52) and Aroen et al (3). The
real prevalence or incidence of cartilage lesions is
not known. There is a variety of underlying causes,
and the time to onset of clinical symptoms mark-
edly varies. Unrecognised or untreated cartilage
defects in younger age as a result of sports injury or
other physical activity may lead to an increased
risk of developing osteoarthritis later in life (60).
A Johns Hopkins prospective cohort study of 1321
former medical students who were followed for a
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median of 36 years, concluded that young adults
with knee injuries run a considerable risk to devel-
op osteoarthritis (OA), 10 years earlier on average
than the group without cartilage defects in young
age (41). OA is one of the most common disabling
disorders, affecting more than 10% of of the
Western population. In the USA, the “Arthritis
Foundation” (www.arthritis.org, March 2005) esti-
mated the cost to the US economy at nearly
$86.2 billion per year in terms of direct expenses,
lost wages and production. 
CARTILAGE DEFECTS NEED TO BE TREATED EARLY
Since Hunter (1743), we know that cartilage 
has a limited capacity for repair. This originates in
its specific structure and anatomy, and is clearly
linked to age (22). Healthy adult articular cartilage
is a unique tissue in the human body, providing
joints with almost frictionless continuous gliding
motion. It can resist loading forces that are a mul-
titude of the individual’s body weight. It absorbs
mechanical shock and spreads the load over the
underlying subchondral bone plate to reduce
extreme loading conditions. Under normal physio-
logical conditions, articular cartilage continues for
a lifetime to exert these essential biomechanical
functions. Chondrocytes are responsible for syn-
thesis and maintenance of the cartilage extracellu-
lar matrix (ECM). These metabolically active cells
respond to various environmental stimuli including
soluble mediators, matrix composition, mechanical
load and hydrostatic pressure. Cartilage basically
consists of a high amount of water bound within a
fine mesh of collagen fibers and proteoglycans
(aggrecans). This highly specialised architecture
provides the tissue with resilience, biomechanical
resistance and tensile strength, to withstand the
forces in the joint, and to reduce the thickness vari-
ations under load to a remarkable extent. A minor
breach within this proteoglycan architecture causes
a substantial decrease in the mechanical properties
of cartilage (17). Because of a lack of inflammatory
response, a cartilage lesion without damage to the
subchondral plate usually does not heal. When the
subchondral plate has been penetrated, repair tissue
can form but it mainly consists of collagen type I as
in mature scar tissue and will deteriorate over time.
Chondrocyte cell death (apoptosis), insufficient
synthesis of new macromolecules and the release
of inflammatory mediators and catabolic enzymes
characterise the course of cartilage degeneration.
This may eventually lead to destructive osteoarthri-
tis (22). Restoration of the normal homeostasis in
the joint must be the main purpose for reconstruc-
tive biological procedures. Existing axial malalign-
ments, damage to menisci or ligaments and synovi-
tis should also be addressed. The importance of
early biological reconstruction of symptomatic
lesions was highlighted by Mithoefer et al (76).
They found that return to pre-injury sporting level
correlated with a shorter duration of preoperative
symptoms and a lower number of prior operations.
All adolescents with preoperative symptoms of
12 months duration or less returned to pre-injury
level athletics, compared with 33% of those with
time intervals longer than 12 months (79).
TREATMENT OPTIONS FOR CARTILAGE LESIONS
Several surgical biological reconstruction
options exist for the treatment of ICRS
(International Cartilage Repair Society) grade 3
and 4 cartilage lesions in the knee. Arthroscopic
lavage and debridement is meant to clean out debris
and potentially harmful catabolic substances that
cause deterioration of the cartilage matrix and
inflammation of the joint (8, 12, 42, 58, 59). Marrow
stimulation recruits bone marrow stem cells from
the underlying bone marrow through abrasion of
the subchondral plate, drilling or microfractur-
ing (12, 58, 82, 89, 94). These cells within their blood
clot will reorganise into a repair tissue covering the
original cartilage defect that was debrided back to
stable borders. These techniques lead to the devel-
opment of predominantly fibrous scar tissue (56)
that does not show the biomechanical load bearing
capacity of healthy articular cartilage (21, 23).
Different variations of osteochondral grafting tech-
niques exist to fill cartilage defects in a joint.
Hangody et al (45, 47, 48) developed mosaicplasty
using small autologous osteochondral plugs, Bobic
et al (15, 16) developed the OATS system (osteo-
chondral autograft transplant system) which uses
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larger plugs. Osteochondral allografts can be used
in salvage operations (42). Owing to the risk of dis-
ease transmission and infection, allograft carti-
lage/bone transplantation should be restricted to
cases where size or depth of a defect make alterna-
tive procedures impossible (24, 25, 42). 
Simple transplantation of periosteum or peri-
chondrium cannot be recommended anymore,
because of its predominantly poor short and mid-
term clinical outcome (2, 67). 
Autologous Chondrocyte Implantation (ACI) is
another established and promising technique for
the repair of cartilage lesions in the knee.
CLINICAL RESULTS OF THE CURRENT TREATMENT OPTIONS
The early optimistic results of lavage and lavage
combined with debridement (32, 36, 55) are the sub-
ject of much controversy, especially since a recent-
ly published prospective randomised and placebo
controlled trial by Moseley et al (78). Hubbard (55)
reported an 80% success rate with debridement
after one year, decreasing to 59% at 5 years, in a
randomised controlled trial comparing debride-
ment and lavage alone, in patients who had not
undergone previous operations. Ogilvie-Harris and
Fitsialos (80) reported similar results.
Bert reported that the fibrocartilage repair tissue
resulting from arthroscopic abrasion arthroplasty
for cartilage lesions in otherwise healthy joints last-
ed only up to 4 years (12, 13). Nehrer et al (79) exam-
ined failed abrasion treatment and reported a mean
time to failure of 21 months. Examination of the
failed repair revealed soft, fibrillated tissue, fre-
quently with central degeneration. The short term
clinical results with microfracture are mostly
good (61, 82). Steadman et al (93) published good
long term (7 to 17 years, mean 11.3 years) retro-
spective results in a selected patient population
with small to medium sized defects (2.77 cm2).
Concomitant pathology was not described and the
publication did not include large and deep osteo-
chondral defects (93). Marrow stimulation tech-
niques have much less favourable results once the
fourth decade has passed (49, 93). A study by
Mithoefer et al (77) showed that microfracture can
result in significant functional improvement at a
minimum follow-up of two years. The best short-
term results are observed with good fill grade, low
body-mass index, and a short duration of preopera-
tive symptoms. The worst results were seen in
patients with a body-mass index of > 30 kg/m2 (p <
0.05). On magnetic resonance imaging, the fill
grade correlated with the knee function scores (77).
A longer follow-up of the patients showed a wean-
ing effect of the repair tissue and similar findings
were reported by Kreuz et al who found a gradual
degradation of the ICRS scores after 18 months
(62). Brown looked at the repair cartilage overlying
the microfracture which generally was depressed
with respect to native cartilage. There was a
marked propensity for bony overgrowth with loss
of adjacent cartilage evident with progressive fol-
low-up (21). 
The results of mosaicplasty are generally good
in small and medium size defects (46, 48, 57). The
applicability of this method remains limited due to
the restricted donor surface area, donor site mor-
bidity and problems in achieving satisfactory sur-
face congruence, thickness and filling. Hangody et
al advise to restrict indications to defects 4 cm2 or
less, based on their results in a large group of
patients with a follow-up up to 10 years (46). 
The role of allograft tissue transplantation for
post-traumatic defects has been reduced to defects
larger than 3 cm in diameter and 1 cm in depth
owing to recent advances in other techniques for
cartilage repair and resurfacing (4, 6).
ACI has now been used worldwide in approxi-
mately 15000 cases. In a clinical evaluation of
244 patients followed for two to ten years, subjec-
tive and objective improvement was seen in a large
number of patients with an ICRS grade 3 or 4
femoral condylar lesion or osteochondritis disse-
cans (20). The percentage of good to excellent
results was high (84% to 90%) for patients with
different types of single femoral condylar lesions,
whereas it was lower (mean : 74%) for those with
other types of lesions (84, 85). In order to study the
long-term durability of autologous chondrocyte
transplantation, 61 patients were followed for 5 to
11 years (mean : 7.4 years) after the surgery. At
2 years, 50 of the 61 patients had a good or excel-
lent result. This increased to 51 of the 61 patients at
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the 5 to 11-year evaluation. The total failure rate
was 16% (10 of 61) at a mean of 7.4 years. All fail-
ures of ACI occurred in the first 2 years, so a high
percentage of the patients who had a good to excel-
lent result at 2 years retained this result at the time
of long-term follow-up. Knutsen et al (61) studied
80 patients who had symptomatic focal cartilage
lesions of the femoral condyles measuring 2 to
10 cm2. The patients were treated at four hospitals
and were randomised into two groups : those treat-
ed with autologous chondrocyte implantation and
those treated with microfracture. At 2 years, the
outcomes were slightly but not significantly better
in the patients treated with microfracture than with
ACI, but both groups had acceptable short-term
clinical results (61). ACI and mosaicplasty are both
claimed to be successful for the repair of articular
cartilage defects in the knee but there have been
only two comparative studies showing conflicting
results. Bentley et al (10) published a randomised
controlled trial comparing mosaicplasty with ACI
in 100 patients with a mean age of 31.3 years
(range : 16 to 49) and with a symptomatic lesion of
the articular cartilage in the knee which was suit-
able for cartilage repair. Most lesions were post-
traumatic with a mean defect size of 4.66 cm2. The
mean duration of symptoms was 7.2 years. The
mean follow-up was 19 months (range : 12 to 26).
Functional assessment using the modified
Cincinatti and Stanmore scores and objective clini-
cal assessment showed that 88% had excellent or
good results after ACI compared with 69% after
mosaicplasty. Arthroscopy at one year demonstrat-
ed excellent or good macroscopic repair in 82%
after ACI and in 34% after mosaicplasty. In this
prospective randomised clinical trial, ACI has
shown superiority over mosaicplasty for the repair
of articular defects in the knee. The results for ACI
are comparable with those in other studies, but
those for mosaicplasty are less favourable in larger
lesions (10). Horas et al (54) performed a prospec-
tive clinical study to investigate the two-year out-
come in forty patients with an articular cartilage
lesion of the femoral condyle who had been ran-
domly treated with either transplantation of an
autologous osteochondral cylinder or implantation
of autologous chondrocytes. Both treatments
resulted in a decrease in symptoms. However, the
improvement obtained with ACI lagged behind the
improvement achieved by osteochondral cylinder
transplantation. Histologically, the defects treated
with ACI were primarily filled with fibrocartilage,
whereas the osteochondral cylinder transplants
retained their hyaline character, although there was
a persistent interface between the transplant and the
surrounding original cartilage. Limitations of this
study included the small number of patients, the
relatively short (two-year) follow-up, and the
absence of a control group (54). Krishnan et al (63)
identified a number of favourable factors for ACI
with a collagen membrane (ACI-C) : younger
patients with higher pre-operative modified
Cincinnati scores, a less than two-year history of
symptoms, a single defect, a defect on the trochlea
or lateral femoral condyle and patients with fewer
than two previous procedures on the index knee.
Revision ACI-C in patients with previous failed
ACI and mosaicplasty produced significantly infe-
rior clinical results. Gender (p = 0.20) and size of
the defect (p = 0.97) did not significantly influence
the outcome (63).
AUTOLOGOUS CHONDROCYTE IMPLANTATION
ACI consists of a two- step procedure. In the first
step, which is arthroscopic, a small cartilage biop-
sy is taken from a lesser weight bearing area of the
affected joint. About 200-300 milligram of carti-
lage is harvested from the joint and sent to a dedi-
cated laboratory where the cells are enzymatically
released from the cartilage tissue and brought in
monolayer culture to expand the number of cells
under cGMP (current Good Medical Practice) con-
ditions. After approximately four to five weeks of
cell culture, cells have multiplied sufficiently to be
collected. The second step of the procedure
requires an arthrotomy to inject a suspension of
articular chondrocytes (approximately 1  106 cells
per cm2 defect surface), without carrier material,
underneath a periosteal flap or collagen membrane. 
The second step is followed by a patient tailored
rehabilitation program.
To consistently obtain expanded chondrocytes,
able to produce a stable cartilage in vivo, cultures
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have to meet the highest standards of quality, safe-
ty and efficacy (11, 31, 38, 102). The purity of each
delivered cell product, including the number of
viable cells, the identity of the cells ( i.e. chondro-
cytes) and the absence of contaminants have to be
guaranteed.
In vitro expansion of articular chondrocytes nor-
mally results in dedifferentiation and loss of in vivo
cartilage formation. A newly developed “potency
assay” using molecular markers monitors the
capacity of expanded articular chondrocytes to
form stable cartilage in vivo and their ability to
withstand mineralisation, vascular invasion and
replacement by bone. The evaluation of the carti-
lage-forming ability in vivo may be informative for
successful cell-based joint surface defect repair
protocols (31).
Criteria for ACI
At this moment ACI is indicated for biological
reconstruction of post-traumatic ICRS grade 3 and
4 cartilage defects in the knee (table I). Before ACI
is applied for the treatment of degenerative/early
focal osteoarthritic cartilage lesions, the results of
ongoing clinical trials have to be awaited.
The current general principles for ACI are :
1. Children have high intrinsic regenerative capac-
ities and ACI should not be applied as a first line
treatment, before radiological closure of the epi-
physis (39). The upper age limit is approximate-
ly 50 years. There is no absolute upper age
limit, because calendar age does not always
reflect the biological age or the condition of the
afflicted joint. Thus in patients over 50, carti-
lage cells can be expanded and implanted (5, 31,
50, 85).
2. A total defect size of 2 cm2 up to 12 cm2 is a
good indication for ACI. Clinical results in the
treatment of joints other than the knee are
promising, but no recommendations can be
given yet for the application of ACI. The opti-
mal indication is a full thickness defect with an
intact subchondral plate. For deeper osteochon-
dral defects and adult osteochondritis dissecans,
exceeding a depth of more then 6 to 8 mm, a
bony reconstruction is needed (84).
3. Before ACI is scheduled, the internal structures
of the knee are best visualised with MRI.
Cartilage specific sequences are essential in the
evaluation of the joint surface. Arthroscopic
inspection remains the gold standard to evaluate
the lesion and confirm the need for ACI or an
alternative resurfacing methods. 
4. Results of previous surgery on the cartilage
should be awaited first. There should be a
period of at least 6 months between a failed
marrow stimulation technique and any new
surgery to allow initial healing of the subchon-
dral plate.
Chondrocyte implantation technique
Surgical technique for defect preparation
In most cases, an arthrotomy of the knee is nec-
essary to reach the defect. In some instances a
mini-arthrotomy or arthroscopy can be used.
Defect preparation itself must be very thorough.
The defect has to be brought back to stable hyaline
cartilage borders, perpendicular to the surface. The
defect bed can be debrided back to the subchondral
bone, ideally keeping the calcified layer intact. A
breach in (or damage to) the subchondral plate
must be avoided as much as possible. Bleeding can
Acta Orthopædica Belgica, Vol. 73 - 2 - 2007
Table I. — Intra-articular status as criteria for ACI
1. Intact corresponding joint surface (maximal ICRS grade 2 damage : see website.
International Cartilage Repair Society www.cartilage.org).
2. Intact load bearing capacity of the surrounding cartilage.
3. Functional meniscus (partial resection to maximum 50% of the total volume is allowed).
4. Maximally two separate defects.
5. Full range of motion.
6. Intact (repaired) ligaments, physiologically correct(ed) lower limb axis.
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be stopped using adrenaline soaked sponges, fibrin
glue or gentle impaction of the bone. All fibrocarti-
lage present in the bottom of the defect has to be
cleaned out (75).
Defect coverage
Currently two methods to cover the defect are
used in Europe (7, 43) : 1) A periosteal flap procured
from the ipsilateral proximal tibia ; 2) A tested and
approved collagen membrane with CE-mark
(Chondro-Gide®, Geistlich AG, Switzerland).
Periosteal flap
Normally this flap is taken from the proximal
tibia below the pes anserinus. Because of shrinkage
it must be larger than the size of the defect (2 mm
in all directions). This flap is sutured into the defect
using atraumatic and resorbable suture material.
With precise size match and adequate technique a
watertight closure of the defect is achieved using
separate stitches or a running suture. The suture
knots have to rest on the periosteal flap. At the
proximal pole of the defect a small opening is left
to host a venous catheter of usually 14 Gauge.
Water tightness is tested first with saline. If there is
still leakage of fluid, additional suture points can
be added. Ideally only after water tightness is
attained, fibrin glue is applied and the joint is taken
through a range of motion to check stability of the
construct. After re-aspiration of the saline, the cell
suspension is injected beneath the flap. First the
cell suspension is reconstituted by gently shaking
and rolling the vial in both hands. Then the cells are
aspirated from the vial using a tuberculin syringe
with a 14 Gauge catheter. Repeated aspiration and
re-injection in the vial has to be avoided to prevent
shear forces and rupture of the cell membranes.
After injection a last suture point is placed at the
injection site and the wound is closed in layers
without suction drainage (19, 97).
The most frequently reported complication in
ACI as applied so far is implant hypertrophy.
According to current insights this is coming from
the periosteal flap and leads to additional surgery in
10 to 25% of cases (43, 51, 101). The extra skin inci-
sion for prelevation of the periosteal flap causes
extra morbidity for the patient. Early loosening of
the periosteal flap can lead to failure of the
implant (79).
Recent developments
Through the development of appropriate bioma-
terials for implant coverage, the reported problems
with traditional ACI can hopefully be solved and
the indications can be broadened (34, 96-98). Several
biomaterials of natural or synthetic origin are under
clinical evaluation at his time and the first encour-
aging results have been reported (34, 43, 70, 83, 90).
Steinwachs et al and Bentley et al (7, 95) both have
published encouraging results of ACI using a colla-
gen type 1/type 3 membrane.
Matrix coupled ACI
Implantation of isolated chondrocytes encapsu-
lated in different artificial scaffolds such as syn-
thetic polymers [carbon fiber (18), polylactic acid
and polyglycolic acid (37) or biological matrices
[demineralised bone matrix (14), collagen (26, 91, 98,
99), hyaluronan (70, 83, 92), fibrin (53, 97), alginate (1,
28, 30, 33, 64, 71, 98) for chondral and osteochondral
lesions has been reported. Examples are MACI
(Matrix associated ACI) and Hyalograft C (FAB,
Bologna, Italy) both are under investigation (6, 70),
but prospective randomised trials are needed before
advocating a broader use. 
The artificial matrices should be biodegradable
at the appropriate rate and biocompatible to allow
the cells to colonise the scaffolds. The chondro-
cytes must be capable of multiplying and maintain-
ing their original phenotype with the production of
cartilage-specific matrix components such as
aggrecan and type II collagen. The artificial matri-
ces offer the advantage of an initial support to the
chondrocytes, making the implant in theory initial-
ly biomechanically superior to the original tech-
nique of injecting the cells as a suspension under a
periosteal flap.
Allogeneic chondrocyte implantation
When allogeneic chondrocytes are used, the sur-
gical procedure can be performed in one step, but
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the long term safety of the use of allogeneic cells
is not known, and therefore their use needs to
be restricted to experimental treatments in well-
defined patient populations and using patient
consent forms. 
Follow-up and rehabilitation
In the early phase the graft needs protection.
Training principles and guidelines specific for car-
tilage repair need to be identified more closely in
the future (44). The primary goals of rehabilitation
are stimulating local adaptation/remodelling of the
repair and return to previous function. Within the
wide array of rehabilitation schedules in the litera-
ture, there is an overall agreement that controlled
weight bearing for graft protection is a necessity.
The way this is achieved though, varies substantial-
ly. 
There is no standard rehabilitation schedule for
mobilisation and functional strength training, in
other words, rehabilitation must be tailored to the
individual patient.
Most important is the localisation of the repair
site and its size. For a defect in the tibiofemoral
joint immediate full range of movement (FROM) is
allowed with very gentle build up. Weight bearing
is allowed two weeks after implantation with 10 kg
weekly increments, to reach full weight bearing at
8 to 10 weeks. Additional physiotherapy measures
are useful (e.g. closed kinetic chain exercises).
Sports activities that do not cause overload of the
knee are allowed after three months, e.g. swimming
and stationary bicycle. Circulation exercises for the
knee are crucial for nutrition of the newly forming
tissue (44, 95). 
In patellofemoral defects immediate weight
bearing is allowed as tolerated. Range of motion is
restricted in the first six weeks and only then is
FROM allowed. 
Other factors are age, previous activity level,
concomitant surgical procedures and patient com-
pliance. Continued patient motivation over a longer
time is crucial, due to the extent of the rehabilita-
tion over time.
Evaluation of results after ACI
It is important for the evaluation of ACI to cap-
ture and report adverse events, peri-operative com-
plications and failures in combination with their
probable cause (e.g. cell quality, indication, clinical
outcome, etc). This guarantees good clinical out-
come and in the end the quality assurance of this
method (9, 101). At this moment we advise a
prospective follow-up of the patients using validat-
ed clinical scoring systems (e.g. Knee injury and
Osteoarthritis Outcome Score (KOOS) or ICRS)
preoperatively and at least once a year after implan-
tation. The evaluation has to capture subjective and
objective parameters. The simultaneous use of dis-
ease specific and generic scores (Lysholm, Tegner,
Cincinati, SF 36) is an adjunct. Morphological con-
trol of defect regeneration is advised using MRI
with cartilage specific sequences, also at least at
one year and yearly thereafter. Recommended
sequences are T2, proton density, 2D Fast Spin
Echo and 3D Gradient Echo (ICRS imaging
recommendations : www.cartilage.org) (72, 73, 86).
Second look arthroscopy
Second look arthroscopy is only recommended
in case of justifiable complications or in individual
cases that are ethically defendable for scientific
reasons, only after a thorough and full explanation
to the patient (informed consent procedure).
Acta Orthopædica Belgica, Vol. 73 - 2 - 2007





Malalignment if not cor-
rected


















152 J. VANLAUWE, F. ALMQVIST, J. BELLEMANS, J.-P. HUSKIN, R. VERDONK, J. VICTOR
Histological and MRI evaluation
To increase the validity of histological evalua-
tion at least two independent experts in the field
have to examine the biopsy. The biopsy, a 1cm
long cartilage-bone plug, is collected using a
cannula of maximum 2mm diameter. The analysis
is best classified according to ICRS standards (68).
The major limitation of a biopsy is that it only
constitutes a momentary view of a certain zone of
the repair tissue. In a study of 94 patients with 2- to
9-years follow-up, Peterson et al found that the
results differed depending on the defect location.
Histological analysis of 37 biopsies of those
patients showed a correlation between hyaline-like
tissue and good to excellent clinical outcome (85).
Roberts et al (87) looked at 10 biopsies between 9
and 30 months and saw a continuous remodelling
from an initial fibro-cartilaginous matrix via enzy-
matic degradation and synthesis of newly formed
type II collagen. The findings of this study indicate
that ACI is not only capable of cartilage repair but
in some cases also capable of regeneration. 
Evaluation of the repair site by other means than
a biopsy is a necessary next step in the study of
treatment results. The role of MRI in the evaluation
of cartilage lesions has been the subject of contro-
versy. Gelb et al (40) in 1996 concluded that MRI
had low sensitivity for chondral lesions, whereas
Roberts and colleagues in 2003 found better
results (40, 88). Interestingly, Roberts et al also
noted that the quality of cartilage inproved over
time. Brown et al found in a non-randomised con-
trolled trial, that sensitive MRI techniques show
better results with ACI than with microfracture (21).
Marlovits et al (72) in 2005, studied the validity and
reliability of MRI in the assessment of autologous
chondrocyte implantation (ACI) in the knee joint
2 years after implantation. Nine pertinent variables
were analysed with high-resolution MRI, including
filling of the defect, integration of the border zone
to the adjacent cartilage, the subchondral lamina,
the subchondral bone, signal intensity of the repair
tissue. An intra-class correlation coefficient (ICC)
of more than 0.81 for 8 of the 9 variables showed
an “almost perfect” agreement. The correlation
between clinical outcome (Visual Analogue Scale
and Knee injury and Osteoarthritis Outcome Score)
and MRI variables as “filling of the defect”, “struc-
ture of the repair tissue”, “changes in the subchon-
dral bone” and “signal intensities of the repair
issue” was statistically significant (72).
Health-economic aspects of ACI
The clinical results obtained in the aforemen-
tioned strict indications, convinced the internation-
al orthopaedic community about the safety and
efficacy of ACI. More and more evidence is com-
ing forth that ACI, when compared to other biolog-
ical procedures, can be economically beneficial. To
obtain reimbursement of expenses this is the third
important criterion, next to safety and efficacy.
Health-economic analyses of longer term prospec-
tive data became available only recently. Minas et
al in a study of 44 patients, concluded that ACI
improved the Quality Of Life (QOL) and was a
cost effective method in circumscribed cartilage
lesions (74). Lindahl et al (65) have examined the
total direct economic burden in 57 patients with
full-thickness chondral lesions of the knee. They
saw a dramatic reduction in costs for absenteeism
(SEK 9,508 = € 991) and medical treatment (SEK
7,050 = € 734), compared to the 10-year period
prior to ACI (SEK 982,457 = € 102339 and SEK
47,000 = € 4895 respectively). Forty-nine of the
57 patients improved clinically as a result of ACI
treatment. A German Cost Effectiveness Analysis
of ACI based on review of the literature concluded
that per 1000 ACI treatments, 310 total knee
replacement operations and 3 surgery-related
deaths can be avoided. The authors concluded that
cost-effectiveness of ACI appears to be superior to
conventional treatment options (100). More recent
mid and long term studies, prospective randomised
trials and better insight in the natural history of car-
tilage lesions bring support to this conclusion (41).
ACI today is the only reliable biological recon-
struction method for localised cartilage defects of
4 cm2 or more. Without biological reconstruction
cartilage injuries predispose to disabling
osteoarthritis, a huge socioeconomic burden to
society. Increasing incongruence of a joint surface,
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which in time becomes a larger defect zone, has
been shown to be an important risk factor in the
development of osteoarthritis (81). ACI helps to
deter costs of reiterative surgery, frequent absen-
teeism and early joint replacement and to postpone
definitive surgery (27).
However, results from a large prospective ran-
domised trial comparing chondrocyte implantation
with microfracture must give better insight in the
place of both techniques in the treatment of carti-
lage defects.
Future developments
Since the original description of ACI in 1994
many new techniques and technique modifications
have been reported (19). To guarantee the continu-
ous improvement of biological effectiveness and to
ensure the safety of any new or modified procedure
to treat cartilage defects (such as matrix implants,
growth factors, etc) research has to be conducted
following these four subsequent steps :
1) In vitro research on growth and differentiation
behaviour of chondrocytes and mesenchymal
stem cells.
2) Experiments in adult animal models to explore
growth and differentiation behaviour of chon-
drocytes, with full documentation on safety and
efficacy, long term (> 6 months) examination of
the implant histology and mechanical testing of
the regenerative tissue.
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Fig. 1. — Femoral cartilage treatment algorithm
Treatment algorithm for cartilage lesions on the femoral condyles. In the treatment of these defects, alignment, ligaments and menis-
cus have to be corrected adequately to increase the long term success rate. In the larger lesions microfracture remains an alternative
depending on patient age, concomitant ACL lesion, time to return to sports and site of the lesion on the condyle.
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3) Exploratory human studies preferably using
less invasive methods, long term examination of
the implant (> 12 months), thorough evaluation
of safety and toxicity and unforeseen events,
examination of the immunological response
(cartilage specific antigens), if possible in a
prospective randomised controlled way.
4) Confirmatory human prospective randomised
studies for long term follow-up of the clinical
results through regular contact with patients.
Results have to be validated, documented and
published.
CONCLUSION
The working group of the Belgian Orthopaedic
societies on cartilage repair in the knee recom-
mends the following treatment modalities :
1. Lavage and debridement are mostly indicated in
degenerative arthritis with mechanical symp-
toms.
2. Microfracture is still the most widely used treat-
ment option for small full thickness lesions
(< 2 cm2) of the femoral condyles and the
patella.
3. For larger lesions (> 2 cm2) ACI should be part
of the treatment strategy. Increasing evidence
from recent studies shows that microfracture
repair tissue has a limited lifespan. Results from
a large prospective randomised trial comparing
chondrocyte implantation with microfracture
might give better insight in the place of both
techniques in the treatment algorithm. 
4. OATS as a “single plug” treatment is a good
option next to microfracture, for smaller
lesions on the femoral condyles, especially in a
young and sportive population. It is not advised
for treatment of patellar lesions. Mosaicplasty
and OATS are good second line options for
full thickness cartilage lesions of less than
3 cm2.
5. In larger lesions fresh osteochondral allografts
can be considered although availability of
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Fig. 2. — Patellar and trochlear cartilage treatment algorithm
Treatment algorithm for patellar and trochlear cartilage lesions. Alignment of the extensor apparatus has to be corrected to increase
the chances for a good long term clinical outcome.
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viable allografts and disease transmission might
be a problem. 
6. Any new and emerging treatment should be
scrutinised against standard treatments before
generalised use as outlined in the recommenda-
tions above. 
The treatment algoritms presented in fig. 1 and 2
adapted from the guidelines presented at the AAOS
in 2005 (69). According to AAOS the lower limit
is 2 cm2.
These guidelines also apply to adult OCD. In
adolescent OCD, conservative treatment is first
choice (35, 66). In a grade 3 lesion, re-fixation of the
fragment or removal and microfracture of the
defect bed are first line treatments. Microfracture
of the lesion bed will cause a “moving up” of the
bone front (21) and can obviate the need for a bone
graft in larger lesions where ACI treatment is like-
ly to follow in a second stage, provided the bony
lesion is not deeper than 6 to 8 mm (84). 
Arthroscopic lavage and debridement and mar-
row stimulation techniques provide only temporary
symptom relief due to the limited durability of the
repair tissue. This may change with the advent of
ACI, showing durable repair tissue and promising
long term results.
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